Showing 4741-4750 of 8890 results for "".
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- From AAD: What's New in Acne and Rosacea?https://practicaldermatology.com/news/from-aad-whats-new-in-acne-and-rosacea/2471565/Dermatologists gathered for the Acne and Rosacea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD,
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- Novel TYK2 Inhibitor Shows Promising Results in Phase 2 Trials for PsOhttps://practicaldermatology.com/news/Novel-TYK2-Inhibitor-Shows-Promising-Results-Phase-2-Trials-PsO/2471545/The TYK2 inhibitor ESK-001 has shown promising safety and efficacy in long-term Phase 2 trials for moderate-to-severe plaque psoriasis, Andrew Blauvelt, MD, FAAD, said in a late-breaking research presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Pacific Northwest Practice Hiringhttps://practicaldermatology.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra